Please login to the form below

Not currently logged in
Email:
Password:

IBS

This page shows the latest IBS news and features for those working in and with pharma, biotech and healthcare.

Ardelyx gets second kidney disease trial win for tenapanor

Ardelyx gets second kidney disease trial win for tenapanor

Shares in Ardelyx rocketed 72% on the back of the new study on the prospect of a second indication for tenapanor to follow constipation associated with IBS, which is under review

Latest news

More from news
Approximately 4 fully matching, plus 93 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... However, FiberOne poked fun at doctors and their scepticism of the legitimacy of IBS.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Positive results from a phase Ib dose-escalation study were

  • Deal Watch January 2017 Deal Watch January 2017

    Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.

  • Deal Watch January 2016 Deal Watch January 2016

    TEN-010, the lead, is a small molecule BET inhibitor that is in two phase Ib oncology studies. ... It is expected that $30m of payments will fall in 2016 relating to the phase Ib studies for SER 262 and a late stage study for SER 109 in CDI.

  • Pharma deals in February 2015 Pharma deals in February 2015

    diarrhoea (IBS-D) label be successful, this figure could rise to $2bn.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics